What have we learnt from Vioxx?. Krumholz, H. M., Ross, J. S., Presler, A. H., & Egilman, D. S. BMJ, 334(7585):120–123, January, 2007.
What have we learnt from Vioxx? [link]Paper  doi  abstract   bibtex   
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues
@article{krumholz_what_2007,
	title = {What have we learnt from {Vioxx}?},
	volume = {334},
	copyright = {© BMJ Publishing Group Ltd 2007},
	issn = {0959-8138, 1468-5833},
	url = {https://www.bmj.com/content/334/7585/120},
	doi = {10.1136/bmj.39024.487720.68},
	abstract = {In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues},
	language = {en},
	number = {7585},
	urldate = {2019-10-04},
	journal = {BMJ},
	author = {Krumholz, Harlan M. and Ross, Joseph S. and Presler, Amos H. and Egilman, David S.},
	month = jan,
	year = {2007},
	pmid = {17235089},
	keywords = {8 Ignorance and funding bias},
	pages = {120--123},
}

Downloads: 0